AULIN SHERRY 4
4 · Xenon Pharmaceuticals Inc. · Filed Dec 19, 2024
Insider Transaction Report
Form 4
AULIN SHERRY
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Shares
2024-12-18$11.58/sh+16,000$185,280→ 16,000 total - Tax Payment
Common Shares
2024-12-18$41.28/sh−4,490$185,347→ 11,510 total - Exercise/Conversion
Common Shares
2024-12-18$9.44/sh+9,334$88,113→ 9,334 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-12-18−16,000→ 6,000 totalExercise: $11.58Exp: 2030-03-11→ Common Shares (16,000 underlying) - Tax Payment
Common Shares
2024-12-18$41.28/sh−2,135$88,133→ 7,199 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-12-18−9,334→ 0 totalExercise: $9.44Exp: 2029-09-15→ Common Shares (9,334 underlying) - Sale
Common Shares
2024-12-18$41.19/sh−11,510$474,097→ 0 total - Sale
Common Shares
2024-12-18$41.23/sh−7,199$296,815→ 0 total
Footnotes (3)
- [F1]Represents the closing price of the Company's common shares on December 17, 2024 for purposes of net settlement calculations.
- [F2]The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.19 to $41.20, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F3]The shares subject to the option are fully vested and exercisable.